EP Patent

EP3616694A1 — Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2020-03-04 · 6y expired

What this patent protects

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapent…

USPTO Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3616694A1
Jurisdiction
EP
Classification
Expires
2020-03-04
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.